Posts tagged “Novartis”
Startup says aloha to name after Hawaii protests; FDA-Pozen update; new Tantalus exec; Apple $400M ebook settlement; Novartis earnings; Visa's new system
In today's Bulldog wrapup of life science and technology news: A L.A. company changes its name after protests in Hawaii; FDA accepts Pozen application; smart grid firm Tantalus in Raleigh names COO; Apple faces $400M ebook settlement; Novartis earnings; and Visa launches new online payment system.
Yahoo earnings fall; N.C. Solar Center's new name; Novartis-Google 'Glass' contacts; Cree expands; Sling's new devices
In today's Bulldog wrapup of technology and life science news: Yahoo takes a hit; N.C. Solar Center gets a new name; Novartis teams with Google for "Glass" contacts; Cree adds space; Sling's new devices.
In the third part of a series offering an overview of North Carolina's global prominence as a home for life science companies, the N.C. Biotechnology Center's Jim Shamp provides an overview of vaccine development.
The revolution has nothing to do with its proximity to the July 4 Independence Day holiday. Rather, it's in the way Flucelvax from Novartis is made at the plant. It's the first flu vaccine produced without antibiotics and preservatives, using a unique biological "soup" called cell culture.
Plans for pharmaceutical giants Novartis, GlaxoSmithKline and Eli Lilly to swap business lines may have shaken up the stock market Tuesday, but work at a Novartis flu vaccine plant in Holly Springs hummed along, and local officials said they expect it to remain that way.
GSK's top executive Andrew Witty says the multiple deals announced early Tuesday with Novartis promise to deliver "broadly sustainable sourced sales growth and improve long-term earnings."
Two drug giants with major operations in the Triangle, Novartis and GlaxoSmithKline, are swapping businesses in two major deals. Meanwhile, Novartis plans to sell its huge Holly Springs plant in a separate deal and also strikes an agreement to sell its animal health business to Eli Lilly. No layoffs are planned, Novartis says.
Drug giants Novartis and GlaxoSmithKline each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the Novartis presentation.
Drug giants GlaxoSmithKline and Novartis each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the GSK presentation.
Square worth $5B?; SAS lands big deal; PayPal's new service; Merck stock jumps; BlackBerry's new sales chief
In our Bulldog blog's tech and life science news update: Square offers shares at $135 each; SAS signs Europe's leading drugstore chain; PayPal testing new service; Merck shares jump on drug news; BlackBerry names new sales chief and lands $250M in investment.
Novartis reportedly is in negotiations with fellow drug giant Merck about a $10 billion asset swap that would include the Novartis human vaccines and animal health businesses. Novartis operates a huge vaccine in Holly Springs and is building an R&D center in RTP.
Several technology and life science firms with a major presence in North Carolina crack the top 25 in the annual World's Best Multinational Workplaces ranking. NetApp, Cisco, Google, Microsoft and Novartis all make the list.
Employees rolled up their sleeves at the $1 billion Novartis Holly Springs vaccine manufacturing facility this week and joined the global throngs marking a revolution in the fight against flu.
Novartis, which operates a huge vaccine manufacturing facility in Holly Springs, is going to hire up to 100 people to staff a new research and development lab in Research Triangle Park. Some jobs also will be moved to RTP from Massachusetts.
International drug maker Novartis will start a strategic review of its units as early as next week and would consider a $10 billion purchase among options for bolstering the business, says new Chairman Joerg Reinhardt.
Europe's biggest drugmaker says it expects to lose $2.7 billion in sales to generic competition this year, 23 percent less than it previously forecast, as it continues to benefit from Ranbaxy Laboratories's failure to market a copycat version of the Diovan hypertension drug.
Several high-tech and life science firms based in North Carolina or who have a large presence here crack the "Best Multinationals" to work for list in Europe. But several of them also drop somewhat from the 2012 list.
Daniel Vasella, who is stepping down as chairman of international drug firm Novartis and decided not to accept a $78 million non-compete agreement, is now talking with the company about a consulting role.